19th Orphan Drugs and Rare Diseases Global Congress 2023 Europe

Collaborations to Accelerate Rare Disease Drug Development and Access

Hilton London Kensington, London, UK

Monday 3rd - Tuesday 4th April 2023

Bionical Emas is the only Contract Research Organization (CRO) to combine Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and generate evidence at every stage of the drug development pathway. Bionical Emas has extensive experience across all phases of clinical research, with a history in rare disease, oncology/heme-oncology and infectious diseases.

Gold Sponsor

The NIHR BioResource is a recallable resource for researchers to support experimental medicine studies and early phase clinical trials. The BioResource comprises a panel of over 200,000 volunteers, with and without health conditions, who have agreed to take part in health research and donated a biological sample for analysis. Combined with health, lifestyle and medical information, researchers can apply to access the detailed genetic and clinical data we hold on prospective participants, who can be selected by genotype and/or phenotype to take part. The BioResource has 18 centres across England, with a national coordinating centre located in Cambridge, UK.

Associate Sponsor

Cisiv is market leading technology solution company, helping Biopharma & MedTech generate real-world data. Cisiv offers a technology platform and patient-centred solution to obtain complex and clinically rich real-world data. Cisiv offers a unique platform for Expanded and Managed Access which allows engagement from all stakeholders, while supporting RWD collection in a compliant way. www.cisiv.com

Associate Sponsor

Almac Clinical Services currently provide services to over 600 Pharmaceutical and Biotech companies worldwide including the top 20 global pharma companies. Guided by our vast clinical supply experience and expertise, we are recognised as one of the leading, multi-faceted, global solution providers within the industry. With extensive experience in programme and supply chain management, Almac Clinical Services has the global reach, expert people, validated processes and cutting-edge technology to deliver comprehensive Managed Access Programmes (MAPs) support to sponsors. From forecasting and production through to storage and distribution, Almac’s dedicated Unlicensed Medicines Services ensure successful review and release of unlicensed medicines. Website: https://www.almacgroup.com/clinical-services/managed-access-programmes/

Associate Sponsor

Dendrite Clinical Systems is a specialist supplier of clinical database software, consultancy and publishing services for the international healthcare sector. With over 30 years’ experience, the company’s global user base extends across hundreds of hospitals, more than 185 national and international databases, in over 80 countries. Dendrite provides registry systems for several national databases in rare diseases and conditions including; Waldenstrom’s macroglobulinemia, Castleman Disease, Alkaptonuria, MPN-SVT, and for BAPS, NOAH, National Audit for Hypospadias, and the Gastroschisis Registry. Email: info@e-dendrite.com Website: www.e-dendrite.com

Exhibitor

The 19th Orphan Drugs & Rare Diseases Global Congress 2023 Europe will be co-located with The 4th Expanded Access Programmes World Congress 2023 Europe,

Shared Exhibit & Networking Area.

Sponsors & Exhibitors will have the benefit of showcasing their Company’s expertise and solutions to attendees from both Events.